Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
8
×
life sciences
national blog main
biotech
national top stories
boston
clinical trials
fda
san francisco blog main
san francisco top stories
eli lilly
indiana blog main
indiana top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
avapritinib
blueprint medicines
calcitonin gene-related peptide
deals
drugs
eptinezumab
erenumab
europe blog main
What
approval
8
×
fda
8
×
drug
won
medicines
therapeutics
therapy
blueprint
cancer
class
developed
medicine
migraine
new
nod
oral
ret
rna
roche
second
address
agency
ago
aimmune
allergy
alnylam
amgen
approved
approves
arguments
awarded
betting
big
billion
biopharma
brexanalone
candidate
candidates
carries
certain
Language
unset
Current search:
approval
×
fda
×
" boston top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines